AVDL Avadel Pharmaceuticals Plc
Price (delayed)
$7.46
Market cap
$720.86M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.51
Enterprise value
$706.44M
Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime
Highlights
Avadel Pharmaceuticals's EPS has surged by 75% YoY and by 33% QoQ
Avadel Pharmaceuticals's net income has soared by 70% YoY and by 33% from the previous quarter
AVDL's quick ratio is down by 31% year-on-year and by 8% since the previous quarter
The company's equity fell by 16% YoY
Key stats
What are the main financial stats of AVDL
Market
Valuations
Earnings
Shares outstanding
96.63M
Market cap
$720.86M
Enterprise value
$706.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
9.73
Price to sales (P/S)
4.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.18
Revenue
$169.12M
Gross profit
$153.84M
Operating income
-$42.4M
Net income
-$48.83M
EBIT
-$38.25M
EBITDA
-$35.57M
Free cash flow
-$46.91M
Per share
Balance sheet
Liquidity
EPS
-$0.51
EPS diluted
-$0.51
Free cash flow per share
-$0.49
Book value per share
$0.77
Revenue per share
$1.78
TBVPS
$1.55
Total assets
$164.24M
Total liabilities
$90.39M
Debt
$36.95M
Equity
$73.85M
Working capital
$85.37M
Debt to equity
0.5
Current ratio
2.75
Quick ratio
2.21
Net debt/EBITDA
0.41
Margins
Efficiency
Dividend
EBITDA margin
-21%
Gross margin
91%
Net margin
-28.9%
Operating margin
-25.1%
Return on assets
-30.1%
Return on equity
-65.7%
Return on invested capital
-38.3%
Return on capital employed
-33.1%
Return on sales
-22.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVDL stock price
How has the Avadel Pharmaceuticals stock price performed over time
Intraday
-0.67%
1 week
-8.69%
1 month
-5.69%
1 year
N/A
YTD
-29.02%
QTD
-4.73%
Financial performance
How have Avadel Pharmaceuticals's revenue and profit performed over time
Revenue
$169.12M
Gross profit
$153.84M
Operating income
-$42.4M
Net income
-$48.83M
Gross margin
91%
Net margin
-28.9%
The net margin has surged by 95% year-on-year and by 45% since the previous quarter
AVDL's operating margin has soared by 95% YoY and by 46% QoQ
Avadel Pharmaceuticals's net income has soared by 70% YoY and by 33% from the previous quarter
The company's operating income has surged by 69% YoY and by 34% QoQ
Growth
What is Avadel Pharmaceuticals's growth rate over time
Valuation
What is Avadel Pharmaceuticals stock price valuation
P/E
N/A
P/B
9.73
P/S
4.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.18
Avadel Pharmaceuticals's EPS has surged by 75% YoY and by 33% QoQ
The stock's price to book (P/B) is 43% less than its last 4 quarters average of 17.3
The company's equity fell by 16% YoY
The price to sales (P/S) is 70% lower than the last 4 quarters average of 14.3
The revenue has grown by 22% from the previous quarter
Efficiency
How efficient is Avadel Pharmaceuticals business performance
Avadel Pharmaceuticals's return on sales has surged by 96% YoY and by 50% QoQ
The ROIC has soared by 73% YoY and by 34% from the previous quarter
The ROE has soared by 69% YoY and by 30% from the previous quarter
AVDL's return on assets has surged by 67% year-on-year and by 33% since the previous quarter
Dividends
What is AVDL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVDL.
Financial health
How did Avadel Pharmaceuticals financials performed over time
The total assets is 82% more than the total liabilities
AVDL's quick ratio is down by 31% year-on-year and by 8% since the previous quarter
Avadel Pharmaceuticals's current ratio has decreased by 24% YoY and by 7% from the previous quarter
The debt is 50% smaller than the equity
Avadel Pharmaceuticals's debt to equity has increased by 25% YoY and by 2% from the previous quarter
The company's equity fell by 16% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.